Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-24

FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a generic fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate for treatment of HIV-1 infection (Or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Snippet

ORIG AP for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)